The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 1953-1960

  Choi, Su Yeon ^a   Kim, Donghee ^a   Kim, Hwa Jung ^a   Kang, Jin Hwa ^a   Chung, Su Jin ^a   Park, Min Jung ^a   Kim, Young Sun ^a   Kim, Chung Hyun ^a   Choi, Seung Ho ^a   Kim, Won ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a   Cho, Sang Heon ^a   Sung, Myung Whun ^a   Oh, Byung Hee ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

CORONARY DISEASE; FATTY LIVER; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 68349155831     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.238     Document Type: Article

References (45)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
2. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 2004;40:1387-95.
3. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9.
4. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-72.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
6. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-40.
7. Ioannou GN, Weiss NS, Boyko EJ et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-51.
8. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-50.
9. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z et al. Prevalence of primary nonalcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856-63.
10. Yano E, Tagawa K, Yamaoka K et al. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001;54:945-51.
11. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;36:371.
12. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
13. Joseph AE, Saverymuttu SH, al-Sam S et al. Comparison of liver histology with ultrasonography in assessing diff use parenchymal liver disease. Clin Radiol 1991;43:26-31.
14. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
15. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539-43.
16. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
17. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
19. WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia Pty Ltd, Melbourne, 2000.
20. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
21. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002;90:18L-21.
22. Targher G, Bertolini L, Padovani R et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004;27:2498-500.
23. Brea A, Mosquera D, Martin E et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case -control study. Arterioscler Thromb Vasc Biol 2005;25:1045-50.
24. Choi SY, Kim D, Kang JH et al. Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease; Relation of non-alcoholic fatty liver disease to carotid atherosclerosis. Korean J Hepatol 2008;14:77-88.
25. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005;11:4838-42.
26. Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391-6.
27. Targher G, Bertolini L, Poli F et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-6.
28. Kern PA, Di Gregorio GB, Lu T et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003;52:1779-85.
29. Kern PA, Ranganathan S, Li C et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280. E745-51.
30. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33.
31. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40. S17-29.
32. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006;54:229-39.
33. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
34. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
35. Sakkinen P, Abbott RD, Curb JD et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002;55:445-51.
36. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36.
37. Targher G, Bertolini L, Zenari L. Hypoadiponectinemia is closely associated with nonalcoholic hepatic steatosis in obese subjects. Diabetes Care 2004;27:2085-6.
38. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
39. Pagano C, Soardo G, Esposito W et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005;152:113-8.
40. Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175-83.
41. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004;3:63-5.
42. Budoff MJ, Nasir K, Mao S et al. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis 2006;187:343-50.
43. Kronmal RA, McClelland RL, Detrano R et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007;115:2722-30.
44. Hense HW, Schulte H, Lowel H et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-45.
45. Liu J, Hong Y, D'Agostino RB Sr et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291:2591-9.